Bioneer

Bioneer Current Liabilities

The Current Liabilities of Bioneer (064550.KQ) as of Nov 6, 2026 is 1.82 B KRW. In the previous year, Current Liabilities was 8.38 B KRW — a change of -78.29% (lower).

Current Liabilities

1.82 BKRW

YoY

-78.29%

Last updated:

Current Liabilities of Bioneer is 2025 1.82 B KRW. Current Liabilities of Bioneer was 2024 8.38 B KRW. It decreases by -78.29% lower compared to the previous year.

The Bioneer Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
24.24 B KRW
Jan 1, 2019
36.03 B KRW
Jan 1, 2020
35.14 B KRW
Jan 1, 2021
50.78 B KRW
Jan 1, 2022
23.54 B KRW
Jan 1, 2023
4.46 B KRW
Jan 1, 2024
8.38 B KRW
Jan 1, 2025
1.82 B KRW
The Bioneer Current Liabilities history
YEARCurrent LiabilitiesYoY
1.82 BKRW-78.29%
8.38 BKRW+88.14%
4.46 BKRW-81.07%
23.54 BKRW-53.65%
50.78 BKRW+44.51%
35.14 BKRW-2.46%
36.03 BKRW+48.62%
24.24 BKRW+19.99%
20.20 BKRW-22.55%
26.09 BKRW-46.74%
48.97 BKRW-4.66%
51.37 BKRW+45.63%
35.27 BKRW+31.83%
26.76 BKRW+89.24%
14.14 BKRW+51.17%
9.35 BKRW-60.64%
23.76 BKRW+39.29%
17.06 BKRW+49.37%
11.42 BKRW+34.98%
8.46 BKRW+51.82%
5.57 BKRW-52.11%
11.64 BKRW+12.95%
10.30 BKRW+43.16%
7.20 BKRW-13.89%
8.36 BKRW+363.73%
1.80 BKRW+7.69%
1.67 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioneer Stock analysis

What does Bioneer do? BIONEER Corp. generates revenue through the sale of biotechnological products, primarily DNA reagents, molecular diagnostic kits, and related services. The company offers DNA and RNA amplification products, Oligo synthesis, gene synthesis services, gene and protein expression, genomics services, and human and veterinary diagnostics kits. It also sells DNA extraction, amplification, and quantitative analysis devices, along with equipment and supplies for biotechnology research. These products are sold to domestic and international markets, including America, China, Japan, India, and Africa, where they serve research institutions, diagnostic laboratories, and healthcare providers. The firm's revenue streams include DNA reagents, molecular diagnostic kits, and DNA diagnostic devices, which are used by customers in the biotechnology, healthcare, and veterinary sectors. DNA amplification products and gene synthesis services are key offerings for research-focused clients, while human and veterinary diagnostics kits target healthcare and animal health markets. Equipment and supplies for biotechnology research are sold to academic and commercial laboratories globally. BIONEER Corp. focuses on developing and selling specialized biotechnology products, with a strong emphasis on DNA and RNA-related technologies. Its product portfolio includes reagents, kits, devices, and services that cater to both research and diagnostic applications. The company's international presence in key markets like America, China, and Japan drives its revenue, with a significant portion coming from the sale of diagnostic kits and DNA analysis equipment. Bioneer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioneer stock

Current Liabilities of Bioneer is 1.82 B KRW in 2025.

Current Liabilities of Bioneer changed from 8.38 B KRW to 1.82 B KRW, representing a -78.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Bioneer since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Bioneer historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bioneer

All Key Metrics — Bioneer